This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus
by Sanghamitra Saha
Healthcare stocks face new risks under Trump, despite their usual defensive reputation.
Top Thematic ETF Ideas for 2024: AI & More
by Neena Mishra
BlackRock's Jay Jacobs discusses best investing themes for 2024.
Top Thematic ETF Ideas for 2024: AI & More
by Neena Mishra
BlackRock's Jay Jacobs discusses best investing themes for 2024.
Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?
by Sanghamitra Saha
Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.
Will 2023 be the Year of Cathie Wood ETFs?
by Sanghamitra Saha
Cathie Wood, famous for the success of Ark Investment¿¿¿s winning products, had faced a miserable fate in 2022. Will her ETFs see success in 2023?
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Moderna ETFs Rallying on COVID-19 Vaccine Booster Shot Update
by Sweta Jaiswal, FRM
Moderna has been rallying on the latest positive booster shot-related update.
Is ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie Wood
by Sanghamitra Saha
Though Cathie Wood's Ark Investment¿¿¿s star products underperformed in 2021 and may continue to lag the broader market in 2022, Wood's fans may follow these ETF strategies to capitalize on her vision.
Moderna ETFs Rallying on COVID-19 Vaccine News to Combat Omicron
by Sweta Jaiswal, FRM
Moderna has been rallying amid concerns surrounding the omicron variant, which has led to possibilities of a rise in demand for COVID-19 vaccines and boosters.